Patents by Inventor Duncan McHale

Duncan McHale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR REDUCING CYTOKINE EXPRESSION
    Publication number: 20240148797
    Abstract: Provided herein are methods and compositions related to Prevotella histicola extracellular vesicles (EVs), and solutions and dried forms (and therapeutic compositions thereof) of Prevotella histicola extracellular vesicles (EVs) for the reduction of IL-8, IL-6, IL-1?, and/or TNF? expression and/or for the treatment of viral infections.
    Type: Application
    Filed: February 23, 2022
    Publication date: May 9, 2024
    Inventors: David Epstein, Duncan McHale
  • COMPOSITIONS AND METHODS FOR REDUCING CYTOKINE EXPRESSION
    Publication number: 20230019986
    Abstract: Provided herein are methods and compositions related to Prevotella bacteria for the reduction of IL-8, IL-6, IL-I?, and/C or TNF? expression and/or for the treatment of viral infections.
    Type: Application
    Filed: February 26, 2021
    Publication date: January 19, 2023
    Inventors: David Epstein, Duncan McHale
  • COMPOSITIONS AND METHODS OF TREATING PSORIASIS AND ATOPIC DERMATITIS USING PREVOTELLA HISTICOLA
    Publication number: 20220339208
    Abstract: Provided herein are methods and compositions related to Prevotella bacteria useful as therapeutic agents, e.g., for the treatment of psoriasis or atopic dermatitis.
    Type: Application
    Filed: August 4, 2020
    Publication date: October 27, 2022
    Inventors: S. M. Abel, Kristie Barth, Mark Bodmer, Taylor A. Cormack, Tanmoy Ganguly, Humphrey Gardner, Andrea Itano, Duncan McHale, Mustafa Noor, Holly Ponichtera, Kritika Ramani, Peter Sandy
  • COMPOSITIONS AND METHODS FOR TREATING IMMUNE DISORDERS USING IMMUNE MODULATING LACTOCOCCUS BACTERIA STRAINS
    Publication number: 20220211773
    Abstract: Provided herein are methods and compositions related to immune modulating Lactococcus strains useful as therapeutic agents. In certain embodiments, provided herein are methods of treating an immune disorder in a subject comprising administering to the subject a bacterial composition comprising Lactococcus lactis cremoris Strain A (ATCC Deposit Number PTA-125368).
    Type: Application
    Filed: January 25, 2022
    Publication date: July 7, 2022
    Inventors: Brian Goodman, Holly Ponichtera, Andrea Itano, Mark Bodmer, Taylor A. Cormack, Maria Sizova, Carolina Baez-Giangreco, Duncan McHale, Kritika Ramani
  • Compositions and methods for treating immune disorders using immune modulating bacteria strains
    Patent number: 11266700
    Abstract: Provided herein are methods and compositions related to immune modulating Lactococcus strains useful as therapeutic agents. In certain embodiments, provided herein are methods of treating an immune disorder in a subject comprising administering to the subject a bacterial composition comprising Lactococcus lactis cremoris Strain A (ATCC Deposit Number PTA-125368).
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: March 8, 2022
    Assignee: Evelo Biosciences, Inc.
    Inventors: Brian Goodman, Holly Ponichtera, Andrea Itano, Mark Bodmer, Taylor A. Cormack, Maria Sizova, Carolina Baez-Giangreco, Duncan McHale, Kritika Ramani
  • NOVEL USES
    Publication number: 20210236513
    Abstract: This invention relates to the compound clozapine and its major metabolite norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic immunoglobulin driven B cell disease. The invention also provides pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 5, 2021
    Applicant: ZARODEX THERAPEUTICS LIMITED
    Inventors: Stephen JOLLES, Houman ASHRAFIAN, Duncan MCHALE
  • CLOZAPINE FOR THE TREATMENT OF A IMMUNOGLOBULIN DRIVEN B CELL DISEASE
    Publication number: 20210236512
    Abstract: This invention relates to the compound clozapine and its major metabolite norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic immunoglobulin driven B cell disease with a T cell component. The invention also provides pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 31, 2019
    Publication date: August 5, 2021
    Applicant: ZARODEX THERAPEUTICS LIMITED
    Inventors: Stephen JOLLES, Houman ASHRAFIAN, Duncan MCHALE
  • CLOZAPINE FOR THE TREATMENT OF IG-E DRIVEN B CELL DISEASES
    Publication number: 20210137941
    Abstract: This invention relates to the compound clozapine and its major metabolite norclozapine and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic IgE driven B cell disease. The invention also provides pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 13, 2021
    Applicant: ZARODEX THERAPEUTICS LIMITED
    Inventors: Stephen JOLLES, Houman ASHRAFIAN, Duncan MCHALE
  • Compositions and Methods for Treating Immune Disorders Using Immune Modulating Lactococcus Bacteria Strains
    Publication number: 20190231829
    Abstract: Provided herein are methods and compositions related to immune modulating Lactococcus strains useful as therapeutic agents.
    Type: Application
    Filed: November 15, 2018
    Publication date: August 1, 2019
    Inventors: Brian Goodman, Holly Ponichtera, Andrea Itano, Mark Bodmer, Taylor A. Cormack, Maria Sizova, Carolina Baez-Giangreco, Duncan McHale